John Sundy MD PhD

Rheumatology•Foster City, CA

Crystal Related, Rheumatoid Arthritis & Related, Clinical Pharmacology

Senior Vice President Clinical Research Gilead Sciences

Join to View Full Profile

Gilead Sciences303 Velocity WayFoster City, CA 94404
Phone+1 650-577-6423

Education & Training

Duke University HospitalFellowship, Allergy and Immunology, 1995 - 1996
Duke University HospitalFellowship, Rheumatology, 1994 - 1995
Duke University HospitalResidency, Internal Medicine, 1991 - 1994
Drexel University College of MedicineClass of 1991, MD, PhD

Certifications & Licensure

NC State Medical License 1994 - 2025
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Fellow (FACR) American College of Rheumatology
Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
Join now to see all

Clinical Trials

Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout Start of enrollment: 2004 Dec 01
Completed
Phase 2
Nitric Oxide, LPS and the Pathogenesis of Asthma Phase II Start of enrollment: 2003 Apr 01
Terminated
Phase 1
Genetics of Asthma - Bronchoscopy Studies Start of enrollment: 2007 Sep 01
Terminated
Phase 1
Nitric Oxide, LPS and the Pathogenesis of Asthma Phase 1 Start of enrollment: 2003 May 01
Completed
Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge Start of enrollment: 2006 Oct 01
Terminated
Phase 1
Role of TLR4 in Environmental Asthma Start of enrollment: 2001 Sep 01
Completed
Phase 1
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma Start of enrollment: 2002 Oct 01
Completed
Phase 3
Strategies for Enhancing Mucosal Immunity to Influenza Vaccine Start of enrollment: 2011 Apr 01
Completed
Early Phase 1
Long-acting Beta Agonist Step Down Study Start of enrollment: 2012 Mar 01
Completed
Phase 4
Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout Start of enrollment: 2012 Jan 01
Unknown status
Phase 2
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP) Start of enrollment: 2012 Jul 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

2 citations
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to ...
Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara, Koichi Amano, Naoki Ishiguro
Modern Rheumatology. 2022-02-28
8 citations
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexat...
Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Naoki Ishiguro
Modern Rheumatology. 2022-02-28
89 citations
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior expo...
Rene Westhovens, William F. C. Rigby, Désirée van der Heijde, Daniel W. T Ching, William Stohl
Annals of the Rheumatic Diseases. 2021-06-01

Press Mentions

The Drug Company That Prospered Without Creating Any DrugsApril 13th, 2023
Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 Was Well-Tolerated and Selectively Expanded Regulatory T CellsJanuary 4th, 2021
Pandion Shares Get a Lift from Positive Top-Line Data in Phase 1a Autoimmune Disease TrialJanuary 4th, 2021
Join now to see all

Professional Memberships

American College of Rheumatology - ACR
Fellow
American Academy of Allergy Asthma and Immunology - AAAAI
Fellow
Alliance for Continuing Education in the Health Professions
Member
American College of Physicians - ACP
Fellow